Refine
Has Fulltext
- yes (9)
Is part of the Bibliography
- yes (9)
Year of publication
- 2015 (9) (remove)
Document Type
- Journal article (7)
- Doctoral Thesis (2)
Language
- English (9)
Keywords
- CXCR4 (2)
- brain (2)
- chemokine receptor (2)
- development (2)
- in vivo imaging (2)
- microenvironment (2)
- neuronal differentiation (2)
- positron emission tomography (2)
- postnatal development (2)
- proteomics (2)
- rat (2)
- Antigen CD8 (1)
- B cells (1)
- Burkitt (1)
- C-Myc (1)
- CD8 (1)
- CTL function (1)
- CXCR4/SDF-1 (1)
- Cytotoxizität (1)
- FDG PET/CT (1)
- Gallium (1)
- Killerzelle (1)
- Lymphom (1)
- NFAT (1)
- NFATc1 (1)
- Rho-GTPases (1)
- Starry Sky (1)
- T cells (1)
- Transkriptionsfaktor (1)
- acute myeloid leukemia (1)
- adenosine kinase (1)
- adrenocortical (1)
- antibodies (1)
- apoptosis, Myc (1)
- autologous transplantation (1)
- axonally transported proteins (1)
- binding (1)
- bone disease (1)
- cancer (1)
- carcinoma metastases to pancreas (1)
- cells (1)
- cerebellum (1)
- cerebral cortex (1)
- coated vesicles (1)
- cycle (1)
- endothelial cells (1)
- enzyme-linked immunoassays (1)
- expression (1)
- goldfish optic nerve (1)
- growth (1)
- growth-associated protein (1)
- heart (1)
- heart failure (1)
- hippocampal stem cells (1)
- hnRNP K (1)
- human brain (1)
- involvement (1)
- kidneys (1)
- leukemia (1)
- lymphoma (1)
- malignancies (1)
- memory B cells (1)
- messenger RNA (1)
- messenger-RNA transport (1)
- multiple myeloma (1)
- mutations (1)
- niche (1)
- olfactory bulb (1)
- phosphatase 2A (1)
- prognostic value (1)
- proteins (1)
- regional development (1)
- stem-cells (1)
- subventricular zone (1)
- surgical treatment (1)
- survival (1)
- target (1)
- therapeutic target (1)
Institute
- Pathologisches Institut (9) (remove)
CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination andpoor prognosis. We evaluated the novel CXCR4 probe [\(^{68}\)Ga]Pentixafor for invivo mapping of CXCR4 expression density in mice xenografted with human CXCR4-positive MM cell lines and patients with advanced MM by means of positron emission tomography (PET). [\(^{68}\)Ga]Pentixafor PET provided images with excellent specificity and contrast. In 10 of 14 patients with advanced MM [\(^{68}\)Ga]Pentixafor PET/CT scans revealed MM manifestations, whereas only nine of 14 standard [\(^{18}\)F]fluorodeoxyglucose PET/CT scans were rated visually positive. Assessment of blood counts and standard CD34\(^{+}\) flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [\(^{68}\)Ga]Pentixafor PET opens a broad field for clinical investigations on CXCR4 expression and for CXCR4-directed therapeutic approaches in MM and other diseases.